Fate Therapeutics Inc (FATE)
3.795
-0.08
(-1.94%)
USD |
NASDAQ |
Apr 26, 16:00
3.795
0.00 (0.00%)
After-Hours: 19:20
Fate Therapeutics Net Income (Quarterly): -44.12M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -44.12M |
| September 30, 2023 | -45.17M |
| June 30, 2023 | -52.76M |
| March 31, 2023 | -18.88M |
| December 31, 2022 | -56.36M |
| September 30, 2022 | -83.56M |
| June 30, 2022 | -76.10M |
| March 31, 2022 | -65.69M |
| December 31, 2021 | -68.62M |
| September 30, 2021 | -43.31M |
| June 30, 2021 | -55.13M |
| March 31, 2021 | -45.09M |
| December 31, 2020 | -53.11M |
| September 30, 2020 | -58.68M |
| June 30, 2020 | -28.07M |
| March 31, 2020 | -33.52M |
| December 31, 2019 | -28.30M |
| September 30, 2019 | -26.61M |
| June 30, 2019 | -23.48M |
| March 31, 2019 | -19.76M |
| December 31, 2018 | -16.03M |
| September 30, 2018 | -16.78M |
| June 30, 2018 | -19.65M |
| Date | Value |
|---|---|
| March 31, 2018 | -14.14M |
| December 31, 2017 | -12.50M |
| September 30, 2017 | -10.68M |
| June 30, 2017 | -9.645M |
| March 31, 2017 | -10.13M |
| December 31, 2016 | -7.94M |
| September 30, 2016 | -8.737M |
| June 30, 2016 | -8.408M |
| March 31, 2016 | -8.377M |
| December 31, 2015 | -7.446M |
| September 30, 2015 | -6.886M |
| June 30, 2015 | -7.779M |
| March 31, 2015 | -7.881M |
| December 31, 2014 | -6.233M |
| September 30, 2014 | -6.603M |
| June 30, 2014 | -6.067M |
| March 31, 2014 | -6.98M |
| December 31, 2013 | -5.739M |
| September 30, 2013 | -6.073M |
| June 30, 2013 | -5.534M |
| March 31, 2013 | -3.548M |
| December 31, 2012 | -4.155M |
| September 30, 2012 | -4.113M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-83.56M
Minimum
Sep 2022
-18.88M
Maximum
Mar 2023
-47.71M
Average
-45.17M
Median
Sep 2023
Net Income (Quarterly) Benchmarks
| Amicus Therapeutics Inc | -33.84M |
| Regeneron Pharmaceuticals Inc | 1.160B |
| Sarepta Therapeutics Inc | 45.66M |
| ADMA Biologics Inc | -17.64M |
| Ocular Therapeutix Inc | -29.22M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.676M |
| Total Expenses (Quarterly) | 49.75M |
| EPS Diluted (Quarterly) | -0.45 |
| Enterprise Value | 68.88M |
| Profit Margin (Quarterly) | -2.63K% |
| Earnings Yield | -43.21% |
| Normalized Earnings Yield | -43.21 |